Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. Dec 1999; 81(8): 1351–1355.
PMCID: PMC2362979

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin

Abstract

The purpose of this study was to evaluate by a retrospective analysis of 53 patients the efficacy of chemotherapy combining etoposide and cisplatin in the treatment of neuroendocrine tumours. The regimen was a combination of etoposide 100 mg m–2 day–1 for 3 days and cisplatin 100 mg m–2 on day 1, given by 2-h intravenous infusion, administered every 21 days. Twelve patients had a well-differentiated and 41 a poorly differentiated neuroendocrine tumour. Toxicity of treatment was assessed in 50 patients and efficacy in 52 patients. Among the 11 patients with a well-differentiated tumour evaluable for tumoural response, only one (9.4%) had a partial response for 8.5 months. Forty-one patients with a poorly differentiated tumour showed an objective response rate of 41.5% (four complete and 13 partial responses); the median duration of response was 9.2 months, the median overall survival 15 months and the median progression-free survival 8.9 months. Haematological grade 3–4 toxicity was observed in 60% of the cases with one treatment-related death, digestive grade 3–4 toxicity in 40% and grade 3 alopecia was constant. No severe renal, hearing and neurological toxicities were observed (grade 1 in 6%, 14%, 72% respectively and no grade >1). We confirm that poorly differentiated neuroendocrine tumours are chemosensitive to the etoposide plus cisplatin combination. However, the prognosis remains poor with a 2-year survival lower than 20% confirming that new therapeutic strategies have to be developed. © 1999 Cancer Research Campaign

Keywords: neuroendocrine carcinoma, treatment, retrospective study

Full Text

The Full Text of this article is available as a PDF (79K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Baudin E, Gigliotti A, Ducreux M, Ropers J, Comoy E, Sabourin JC, Bidart JM, Cailleux AF, Bonacci R, Ruffié P, et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer. 1998 Oct;78(8):1102–1107. [PMC free article] [PubMed]
  • Baudin E, Bidart JM, Rougier P, Lazar V, Ruffié P, Ropers J, Ducreux M, Troalen F, Sabourin JC, Comoy E, et al. Screening for multiple endocrine neoplasia type 1 and hormonal production in apparently sporadic neuroendocrine tumors. J Clin Endocrinol Metab. 1999 Jan;84(1):69–75. [PubMed]
  • Gould VE, Linnoila RI, Memoli VA, Warren WH. Neuroendocrine cells and neuroendocrine neoplasms of the lung. Pathol Annu. 1983;18(Pt 1):287–330. [PubMed]
  • Greenberg RS, Baumgarten DA, Clark WS, Isacson P, McKeen K. Prognostic factors for gastrointestinal and bronchopulmonary carcinoid tumors. Cancer. 1987 Nov 15;60(10):2476–2483. [PubMed]
  • Hainsworth JD, Johnson DH, Greco FA. Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity. Ann Intern Med. 1988 Sep 1;109(5):364–371. [PubMed]
  • Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, Oberg K. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997 Jul;8(7):685–690. [PubMed]
  • Johnson LA, Lavin P, Moertel CG, Weiland L, Dayal Y, Doos WG, Geller SA, Cooper HS, Nime F, Massé S, et al. Carcinoids: the association of histologic growth pattern and survival. Cancer. 1983 Mar 1;51(5):882–889. [PubMed]
  • McDermott EW, Guduric B, Brennan MF. Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg. 1994 Jul;81(7):1007–1009. [PubMed]
  • MANTEL N, HAENSZEL W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959 Apr;22(4):719–748. [PubMed]
  • Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. [PubMed]
  • Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 1997 Feb 15;79(4):813–829. [PubMed]
  • Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991 Jul 15;68(2):227–232. [PubMed]
  • Oberg K. Treatment of neuroendocrine tumors. Cancer Treat Rev. 1994 Oct;20(4):331–355. [PubMed]
  • Pelley RJ, Bukowski RM. Recent advances in diagnosis and therapy of neuroendocrine tumors of the gastrointestinal tract. Curr Opin Oncol. 1997 Jan;9(1):68–74. [PubMed]
  • Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solcia E. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg. 1996 Feb;20(2):168–172. [PubMed]
  • Staren ED, Gould VE, Warren WH, Wool NL, Bines S, Baker J, Bonomi P, Roseman DL, Economou SG. Neuroendocrine carcinomas of the colon and rectum: a clinicopathologic evaluation. Surgery. 1988 Dec;104(6):1080–1089. [PubMed]
  • Warren WH, Faber LP, Gould VE. Neuroendocrine neoplasms of the lung. A clinicopathologic update. J Thorac Cardiovasc Surg. 1989 Sep;98(3):321–332. [PubMed]
  • WILLIAMS ED, SANDLER M. The classification of carcinoid tum ours. Lancet. 1963 Feb 2;1(7275):238–239. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...